ArticleHeadache2026
Beyond symptom: Exploring the analgesic properties of vomiting in patients with migraine.
Article in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was conducted to characterize the prevalence, temporal patterns, and the degree of vomiting-induced migraine pain relief (VIMPR).
backgroundAlthough data in the literature and anecdotal patient reports indicate the occurrence of VIMPR, its detailed characterization remains unstudied. Knowledge gaps are present regarding the extent and the temporal dynamics of pain relief upon vomiting in patients with migraine.
methodsWe conducted an explorative, cross-sectional, questionnaire-based study on patients with migraine referring at the Headache Center of Careggi University Hospital, Florence, Italy (June-December 2023). We assessed vomiting frequency, number of episodes, pain intensity (numerical rating scale [0-10]) for attacks with and without vomiting, temporal relationship between vomiting and VIMPR, pain recurrence patterns, as well as vomiting induction behaviors.
resultsAmong 106 patients with migraine, 82 of 106 (77.4%; 95% confidence interval [CI], 68.5%-84.3%) reported vomiting during attacks. Attacks with vomiting were significantly more painful than those without (median, 9.0 vs. 7.0, Wilcoxon signed-rank test, V = 70, p < 0.001, r = 0.77). VIMPR occurred in 45 of 82 patients (54.9%; 95% CI, 44.1%-65.2%), with 12 of 82 (14.6%) experiencing complete attack cessation whereas 33 of 82 (40.2%) only temporary reduction. Of the 45 patients experiencing VIMPR, onset of pain relief occurred within seconds in 13 of 45 (28.9%), within minutes in 18 of 45 (40.0%), and within hours in 14 of 45 (31.1%). For those with pain recurrence, 57.6% experienced reduced intensity compared to pre-vomiting levels. Voluntary vomiting induction was reported by 22 of 82 patients (26.8%; 95% CI, 18.4%-37.3%) and was more common among those who had experienced VIMPR (18 of 45, 40.0%) compared to those without VIMPR (4 of 37, 10.8%; χ
conclusionsVomiting seems to provide pain relief and/or pain freedom in more than half of patients with migraine. Although the cross-sectional, self-reported nature of our data does not allow definitive conclusions regarding underlying mechanisms, the rapid onset of VIMPR reported by patients and the learned behavior of voluntary vomiting induction are consistent with the involvement of endogenous antinociceptive pathways. Future studies employing neuroimaging techniques, prospective designs, along with the consistent documentation of acute medication use, are needed to elucidate whether VIMPR represents a genuine endogenous neurobiological mechanism and to characterize the potential underlying pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.